Home > Insider Trading > Filing (0000950170-25-010706)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1744659	Akero Therapeutics Inc.	AKRO	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1961273	Patrick Lamy	C/O Akero Therapeutics, Inc. 601 Gateway Blvd, Suite 350 South San Francisco CA 94080	Senior Vp, Commercial Strategy	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2024-12-31	234	$19.69	34,492	No	4	A	Direct
Common Stock	Acquisiton	2025-01-27	4,000	$19.87	38,492	No	4	M	Direct
Common Stock	Disposition	2025-01-27	5,000	$57.03	33,492	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2025-01-27	4,000	$0.00	83,182	$19.87

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
79,182		2033-12-07	No	4	M	Direct

Footnotes

Mr. Lamy is voluntarily reporting the acquisition of these shares on December 31, 2024 pursuant to the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(c) and Rule 16b-3(d).
In accordance with the provisions of the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan, these shares were purchased at 85% of the closing price of the Issuer's common stock on July 1, 2024.
The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 28, 2024, previously adopted by the Reporting Person.
This option shall vest and become exercisable in 48 equal monthly installments, commencing on December 8, 2023.